Existing murine tumour models have a number of disadvantages that limit their usefulness in the investigation of cancer therapy, particularly cytokine therapy. Some syngeneic tumours are immunogenic and when treated with cytokines an allograft response may predominate. Transplantable tumours are often derived from cell lines and produce rapidly growing tumours that are a model for poorly differentiated or anaplastic tumours. Such tumours are not analogous to those human malignancies that respond to cytokines and also may not develop the complex host-tumour relationship of slow growing tumours. Similar disadvantages apply to models of metastases. Human tumour xenografts growing in nude mice are obviously inappropriate for studying any cytokine that may act via the host immune system. Consequently, there is a need for a murine tumour system that more closely resembles human cancer, is metastatic and arises in an immunocompetent animal. A model that also reflects the diversity of growth patterns encountered in human carcinomas, and uses an oncogene implicated in a particular cancer, would have further advantages.
Human c-erbB-2, the human equivalent of the rodent neu oncogene, was found to be amplified in 30% of 189 primary human breast cancers (Slamon et al., 1987) . This amplification had greater predictive value in lymph nodepositive disease than existing prognostic factors. In both invasive, and certain types of in situ carcinoma, a high cytological grade was associated with up-regulation of this gene. In particular, comedo-type ductal carcinoma was a histological type of tumour more frequently associated with c-erbB-2 amplification (Van de Vijver et al., 1988) . This gene is therefore an appropriate candidate in a model tumour system. There are two well-characterised transgenic mouse models of mammary cancer that possess the activated neu oncogene under control of the MMTV-promoter (Muller et al., 1988; Bouchard et al., 1989 (Bouchard et al., 1989) . Because of its closer resemblance to the biology of human disease, we have used the latter model to establish a colony of inbred mice. In this paper we describe the range of tumours, their morphology, biological diversity, metastatic pattern and growth characteristics. We compare these features with the similar data available on c-erbB-2-positive human mammary carcinoma. To enable a preliminary assessment of the potential of these mice as a model for cancer therapy, we have established eight tumours from the colony in nude mice or transgene-negative mice and treated these with a range of cytokines.
Materials and methods

Mice
Three male founder mice on a C57B1/6 x C3H background were obtained from Professor Paul Jolicoeur. These had been generated by microinjecting a 8.2 kb SacII-EcoRI chimeric DNA fragment containing the activated rat c-neu cDNA under transcriptional control of the MMTV long terminal repeat (LTR) (Bouchard et al., 1989) . One-cell The S-phase fraction (SPF) for the diploid tumours was measured using the method of Baisch et al. (1975) . Figure 1 and Table I . Four mice developed two different histological tumour types simultaneously. Consequently tumour incidence is based on number of mice succumbing as a result of tumours and not on numbers of tumours.
Tumour incidence in successive generations
Analysis of the second, third and fourth generation showed a slight decline in the median age of tumour development (17,15 and 15 months respectively). The proportion of tumours that were of mammary origin remained the same.
Change in transgene positivity with successive generation A total of 738 female mice were bred onto a BALB/c background in the first seven generations, of which 391 were transgene positive. There was a gradual and significant decline in the proportion of transgene-positive females born with each successive generation ( Figure 2 ). This observation was originally based on slot-blot results but was confirmed by Southern blotting. The difference between the generations M, mammary; FO1, Harderian gland; _, lymphoma. 
Influence of litter number on tumour development
The influence of litter number on tumour development was studied in the fourth generation. Virgin mice developed fewer mammary tumours, those mice mated only once developed no mammary tumours whereas those mated two or more times had a higher incidence of tumours overall ( Figure 3 ). There was an overall difference between the groups in relation to litter number, (P = 0.003 by Fisher's exact test Twenty-three of the 53 (43%) mammary tumours metastasised to lung (an example is shown in Figure 4c ). Lymph node deposits were sometimes seen near the primary site and carcinoma cells were also seen in the liver sinusoids and the spleen. No metastases were recorded in bone. However these were sought by sectioning spinal cord in 20 of the mice. In humans, the more sensitive technique of bone scintigraphy would normally be used. Of the spectrum of pathology, the micropapillary histological pattern appeared most likely to metastasise to lung, with an incidence of 11/16 (69%) as compared with 12/37(32%) of the non-papillary tumours (P = 0.003, Fisher's exact test).
Harderian gland carcinomas The Harderian gland is a modified sebaceous gland found deep in the orbit of animals with a nictitating membrane. Twenty-four Harderian gland carcinomas were seen, being diagnosed mainly on the basis of a protruberant eye and the presence of fluid and solid tumour behind the eye at post-mortem. Age of onset ranged from 11 to 25 months with median being 18 months. In four cases lung metastases were found on pathological assessment, although no primary was noted post-mortem. Histologically these tumours were papillary in pattern and resembled the more poorly differentiated end of the spectrum found to occur naturally (see Figure 4d ). There was a higher proportion of these tumours in virgin mice than in mated mice. Sixty per cent of Harderian gland carcinomas metastasised to lung. Metastases did not appear to correlate with the grade of the primary tumour. Indeed, in one case, the primary tumour had the appearance of an adenoma but metastases in the lungs were consistent with a malignant Harderian gland carcinoma. There was a statistically significant difference (P = 0.003) between the proportion of Harderian gland tumours metastasising to lung in mated mice as compared with the proportion arising in virgin mice ( 
S-phase fraction analysis
In order to confirm the subjective impression of diversity in this model, both within and between tumour subcategories, we have examined their proliferative rate using S-phase fraction. Thirteen primary mammary tumours were examined and 11 found to exhibit a wide range of S-phase fraction (range 5.6-11.9, median 9.0). In two other mammary tumours there were two clones of tumour preventing analysis of the S-phase fraction of the different aneuploid peaks. One of the 13 mammary tumours was diploid and 12 were aneuploid. Analysis of both aneuploidy and S-phase fraction was possible in 9 of the 13 tumours and these data are shown in Figure 5 . Two primary lymphomas were also examined and the S-phase fraction values were 6.1 and 13.9. each group seven or eight animals were assessable and median survival for the group calculated.
There was a marked diversity between different tumours in their sensitivity to the individual interferons and their combination. With one exception, all the cytokine-treated animals survived longer (but not always statistically so) than control diluent treated. IFN-a treatment caused a significant increase in survival in two of seven different tumour lines (P = 0.003), IFN-y in three of seven (P = 0.02, P = 0.003, P = 0.00 1) and IFN-o/y combinations in three of seven (P = 0.001 or P = 0.003). Three of the tumours failed to respond significantly to either IFN or their combination. Two of the tumours responded significantly to both IFN-x and y, and in only one case did the combination of these work in the absence of a response to the individual cytokine.
Discussion
The rationale for this study was to develop a model for use in preclinical assessment of cancer therapy, in particular cytokine therapy. An unexpectedly diverse range of tumour types and biological behaviours has been observed. The founder mice were reported to develop poorly differentiated metastatic adenocarcinomas of the breast at 7-14 months of age in a stochastic and asynchronous fashion (Bouchard et al., 1989) . As these mice have been backcrossed onto a BALB/c background for eight successive generations, the tumour incidence has been lower and the tumour types have been more varied and have arisen later than in the founder mice (Thomas and Balkwill, 1994) . This may be the result of the BALB/c background, but may also have been affected by differences in animal husbandry, diet, endemic infection and relative crowding of the animals in the two colonies. In this particular model tumours arise after a number of genetic events and all the above factors may contribute.
One notable observation was the decline in transgene positivity with successive generations. Any explanation for this is likely to be complex. It may be that the transgene is not inherited or expressed as a result of the abnormal 'state' of the oncogene in these mice. As a result it may not be feasible to maintain a reproducible and stable model using a colony of transgenic mice. This potential drawback for the assessment of therapy could be overcome by homozygous matings. This is our current strategy now that the colony has reached the eleventh generation. Another Of the two mammary tumour transgenic models involving MMTV-activated neu, the tumours described by Bouchard et al. (1989) bore a greater histological resemblance to human mammary tumours than those described by Muller et al. (1988) . We have seen this characteristic morphology in 35 of the 47 mammary tumours. This bears some resemblance to the histological pattern seen in large-cell or comedo-type DCIS in humans, a histological type of tumour associated with c-erbB-2 amplification (Bartkova et al., 1990) . Features of papillary carcinoma, present to varying degrees in twelve of the tumours, are also consistent with findings in humans and associated with c-erbB-2 positivity. The close similarities between the grade and cytopathology of murine mammary cancer associated with c-neu and the human disease associated with c-erbB-2, is in contrast with those seen in other mammary tumours in oncogene transgenic mice (Halter et al., 1992; Cardiff et al., 1993) .
The resemblance to human tumours also extends to many of the non-mammary tumours arising in the colony. Lymphomas have previously been described in mice transgenic for the normal human c-erbB-2 oncogene (Suda et al., 1990) . These lymphomas were predominantly B cell in origin. All the lymphomas in our colony stained positively with the antibody to c-erbB-2 and were B cell in origin, suggesting that they were related to expression of the transgene. There were five angiosarcomas arising at a number of different sites that did not express the transgene. In the mouse angiosarcomas usually arise in the spleen, liver and subcutaneous tissues, although they account for fewer than 3% of spontaneously arising tumours (Smith and Pilgrim, 1971) . Angiosarcomas tend to be locally invasive and may metastasise to the lungs. This suggests these tumours may not be related to transgene expression, although the incidence is rather high, angiosarcomas being rare in BALB/c mice.
Neoplasms of the Harderian gland form a spectrum and the vast majority arising spontaneously in BALB/c mice tumours are categorised as adenomas. A few progress to adenocarcinomas and metastasise to lung, although the incidence of metastases may be increased by exposure to a number of mutagens and chemicals (Della Porta et al., 1963; Fry et al., 1975; Vesselinovitch et al., 1975) . In our experience Harderian gland carcinomas frequently metastasised to lung in mice that had two litters, but not in virgin mice. This did not appear to correlate with the grade of the primary tumour, which is comparable with the behaviour of spontaneously arising carcinomas. The Harderian gland carcinomas stained positive for c-erbB-2.
The incidence of mammary tumours arising spontaneously in BALB/c mice kept in germ-free conditions varies widely in different studies. They appear to have a relatively low incidence of spontaneous mammary tumours (up to 5% in retired breeding females) (Foster et al., 1982) . Other sources suggest up to 3% in breeding females and 1% in virgin mice (Smith and Pilgrim, 1971; Kalra et al., 1993) during the normal lifespan of the mouse. The incidence of spontaneous lymphomas in BALB/c mice kept in germ-free conditions is less than 3% but again the overexpression of neu suggests that the transgene is involved. The median S-phase fraction value for murine mammary carcinomas arising in this colony is similar to that of human mammary carcinomas (9.0% in these tumours; 9.6% in humans) (Camplejohn et al., 1995) . A higher proportion of the murine tumours were aneuploid than in many human series (11/12 in this study as compared with 18/29 human tumours in Kalra et al. (1993) ) but this is entirely consistent with the poor differentiation of these tumours, and characteristic of their neu positivity.
The unactivated neu oncogene has been reported to be associated with the development of mammary tumours that metastasise to lung in older transgenic mice (Guy et al., 1992) but the activated gene has been linked with aggressive primary tumours with a relatively low incidence of metastasis (Muller et al., 1988; Bouchard et al., 1989 ). In our model, in tumours approaching the 2 cm diameter limit, the incidence of metastases approached 70%, being similar to that seen with the unactivated neu oncogene and making this a useful model for the study of metastasis. This is most likely a consequence of the BALB/c genetic background and the fact that tumours arise later in this model in comparison with the founder mice of Bouchard et al. (1989) .
Our findings with this colony have not been described by others working with mice transgenic for activated c-neu. Indeed the spectrum of tumours more closely resembles that described by Suda et al. (1990) in mice with the unactivated c-erbB-2 oncogene and that seen with MMTV-Ha-ras (Cardiff et al., 1993) . The c-neu proto-oncogene (rat homologue of the human c-erbB-2 oncogene) is a membranebound 185 kDa receptor molecule with tyrosine kinase activity. It shares partial homology with the epidermal growth factor receptor and its role in mammary cancer has been extensively investigated (Slamon et al., 1987) . In a chemically transformed neuroblastoma cell line, rat c-neu is activated by a point mutation, which results in a single amino-acid substitution (valine to glutamic acid) in the transmembrane domain of the protein (Bargmann et al., 1986a) . The mutant neu gene, but not the normal neu gene, can transform NIH3T3 cells (Bargmann et al., 1986b) . Substitution of the corresponding amino acid in human c-erbB-2 protein would require two mutations in the gene. The human c-erbB-2 gene can transform the fibroblasts by overexpression (Di Fiore et al., 1987) . Overexpression of c-erbB-2 and not activation is found in human adenocarcinomas, particularly breast and stomach cancers (Yokota et al., 1986 ; Van der Vijver et al., 1987) .
The breast tumours arising in the colony grew readily in nude mice and such transplants were used in preliminary cytokine therapy experiments. The aim of these experiments was to develop treatment schedules that could be translated to spontaneously arising tumours at a later date; to assess the inherent cytokine sensitivity of these tumours and to assess the inter-tumour variation in response. In general IFN therapy had a modest beneficial effect on survival but the response was not dramatic and only two complete regressions were recorded in over 150 treated tumours. Three of the tumour lines failed to respond significantly to either IFN or their combination. This lack of response is similar to the human experience with these cytokines in solid tumours (Sparano and O'Boyle, 1992) . The diversity of response of individual tumours is again analogous to results obtained in clinical trials with several cytokines (Gutterman, 1994) .
Recombinant murine IL-12 has been tested against a number of murine tumour models (Brunda et al., 1993) and shown to have potent in vivo anti-tumour and anti-metastatic effects. The preliminary results were encouraging and certainly warrant further investigation. IL-12 would seem to be the most suitable candidate for treatment of spontaneous tumours in this model.
To date there has been limited use of transgenic mice for preclinical assessment of cancer therapy. One of the few studies involved the use of chemotherapy in hybrid transgenic mice (Dexter et al., 1993) . However the histopathology of the tumours was not comparable with that seen in humans.
In summary, this model, which demonstrates a histological and biological convergence of human and murine mammary cancer, has potential for evaluating the spectrum of cancer therapies and as such is highly relevant to the assessment of novel therapies for c-erbB-2-positive breast cancer. However further manipulations, such as dietary change, hormonal therapy or administration of mild carcinogens, are required to increase the incidence, and decrease the age of onset, of tumours in the colony.
